vida: extract claims from 2025-12-01-who-glp1-obesity-guideline-conditional

- Source: inbox/queue/2025-12-01-who-glp1-obesity-guideline-conditional.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints.md

@@ -10,17 +10,17 @@ agent: vida
 scope: structural
 sourcer: RGA (Reinsurance Group of America)
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier]]"]
-supports:
+supports: ["GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations", "The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes"]
-- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
+reweave_edges: ["GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation|related|2026-04-09", "The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes|supports|2026-04-14"]
-- The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms"]
-reweave_edges:
-- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation|related|2026-04-09
-- The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes|supports|2026-04-14
-related:
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
 ---
 
 # GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
 
-The SELECT trial demonstrated 20% MACE reduction and 19% all-cause mortality improvement in high-risk obese patients. Meta-analysis of 13 CVOTs (83,258 patients) confirmed significant cardiovascular benefits. Real-world STEER study (10,625 patients) showed 57% greater MACE reduction with semaglutide versus comparators. Yet RGA's actuarial modeling projects only 3.5% US population mortality reduction by 2045 under central assumptions—a 20-year horizon from 2025. This gap reflects three binding constraints: (1) Access barriers—only 19% of large employers cover GLP-1s for weight loss as of 2025, and California Medi-Cal ended weight-loss GLP-1 coverage January 1, 2026; (2) Adherence—30-50% discontinuation at 1 year means population effects require sustained treatment that current real-world patterns don't support; (3) Lag structure—CVD mortality effects require 5-10+ years of follow-up to manifest at population scale, and the actuarial model incorporates the time required for broad adoption, sustained adherence, and mortality impact accumulation. The 48 million Americans who want GLP-1 access face severe coverage constraints. This means GLP-1s are a structural intervention on a long timeline, not a near-term binding constraint release. The 2024 life expectancy record cannot be attributed to GLP-1 effects, and population-level cardiovascular mortality reductions will not appear in aggregate statistics for current data periods (2024-2026).
+The SELECT trial demonstrated 20% MACE reduction and 19% all-cause mortality improvement in high-risk obese patients. Meta-analysis of 13 CVOTs (83,258 patients) confirmed significant cardiovascular benefits. Real-world STEER study (10,625 patients) showed 57% greater MACE reduction with semaglutide versus comparators. Yet RGA's actuarial modeling projects only 3.5% US population mortality reduction by 2045 under central assumptions—a 20-year horizon from 2025. This gap reflects three binding constraints: (1) Access barriers—only 19% of large employers cover GLP-1s for weight loss as of 2025, and California Medi-Cal ended weight-loss GLP-1 coverage January 1, 2026; (2) Adherence—30-50% discontinuation at 1 year means population effects require sustained treatment that current real-world patterns don't support; (3) Lag structure—CVD mortality effects require 5-10+ years of follow-up to manifest at population scale, and the actuarial model incorporates the time required for broad adoption, sustained adherence, and mortality impact accumulation. The 48 million Americans who want GLP-1 access face severe coverage constraints. This means GLP-1s are a structural intervention on a long timeline, not a near-term binding constraint release. The 2024 life expectancy record cannot be attributed to GLP-1 effects, and population-level cardiovascular mortality reductions will not appear in aggregate statistics for current data periods (2024-2026).
+
+## Supporting Evidence
+
+**Source:** WHO Global Guideline, December 2025
+
+WHO projects <10% global access by 2030 (approximately 100 million people out of >1 billion with obesity), providing the most authoritative access constraint projection to date and confirming that population-level mortality impact will be severely delayed by structural barriers

domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md

@@ -39,3 +39,10 @@ Exercise helps preserve muscle mass and sustain weight loss after GLP-1 cessatio
 **Source:** PubMed 41696398 systematic review, 33 SUD trials
 
 The continuous treatment requirement extends beyond metabolic conditions to substance use disorders. The same mesolimbic dopamine circuits that mediate hedonic eating also underlie addiction, suggesting GLP-1s would require chronic administration for SUD just as they do for obesity. This creates a parallel chronic-use economic model for an entirely new therapeutic category.
+
+
+## Supporting Evidence
+
+**Source:** WHO Global Guideline, December 2025
+
+WHO guideline specifies GLP-1 therapies for 'long-term obesity treatment (defined as ≥6 months continuous therapy)' and cites 'unclear maintenance and discontinuation protocols' as a reason for conditional rather than strong recommendation, confirming the chronic use requirement

domains/health/who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap.md

@@ -10,7 +10,7 @@ agent: vida
 scope: structural
 sourcer: WHO
 supports: ["glp-1-access-structure-inverts-need-creating-equity-paradox"]
-related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap", "who-glp1-conditional-endorsement-signals-system-readiness-gap", "who-glp1-behavioral-supplement-low-certainty-evidence"]
 ---
 
 # WHO endorsed GLP-1s for obesity treatment in December 2025 while USPSTF maintains its 2018 recommendation excluding pharmacotherapy creating the largest international-US preventive coverage policy gap in modern history
@@ -22,3 +22,10 @@ Meanwhile, USPSTF's most recent obesity recommendation dates to 2018 and explici
 This creates an unusual structural asymmetry: patients in high-income countries with WHO-aligned guidelines (Canada, UK, Australia) may access covered GLP-1 obesity treatment, while US patients cannot get ACA-mandated coverage without comorbidities like diabetes or cardiovascular disease. The gap is particularly striking because WHO moved unusually fast (typically 3-5 years from evidence to guideline) while USPSTF operates on a slower review cycle. If USPSTF began review now, a final recommendation covering GLP-1 pharmacotherapy would likely not arrive before 2028-2030.
 
 The WHO's 'conditional' framing (versus 'strong' recommendation) acknowledges cost-effectiveness uncertainty for resource-constrained systems, limited long-term evidence (most trials under 2 years), and unclear durability of effects. WHO explicitly positioned GLP-1s as 'ONE component within a comprehensive approach requiring healthy diets, physical activity, professional support, and population-level policies' and stated that countries must 'consider local cost-effectiveness, budget impact, and ethical implications' before adoption. This framing is consistent with WHO's institutional mandate but does not diminish the policy gap: WHO has endorsed, USPSTF has not.
+
+
+## Extending Evidence
+
+**Source:** WHO Global Guideline, December 2025
+
+WHO issued conditional recommendation December 2025 with explicit equity and access concerns, while USPSTF maintains 2018 exclusion. The WHO conditionality is based on 'high current costs' and 'inadequate health system readiness' which directly impacts ACA mandatory coverage pathway that depends on USPSTF grade A or B recommendation

domains/health/who-glp1-conditional-recommendation-reflects-structural-access-barriers-not-clinical-efficacy-uncertainty.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: "The WHO's first GLP-1 guideline cites moderate-certainty efficacy evidence but issues only a conditional recommendation due to cost, health system readiness, and equity concerns, projecting fewer than 10% of eligible patients will have access by 2030"
+confidence: likely
+source: WHO Global Guideline on GLP-1 Medicines, December 2025
+created: 2026-04-26
+title: "WHO issued conditional (not strong) recommendation for GLP-1 obesity treatment with <10% projected global access by 2030 confirming structural barriers limit population-level impact of clinically proven interventions"
+agent: vida
+sourced_from: health/2025-12-01-who-glp1-obesity-guideline-conditional.md
+scope: structural
+sourcer: World Health Organization
+supports: ["medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm", "glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "glp-1-access-structure-inverts-need-creating-equity-paradox"]
+related: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp-1-access-structure-inverts-need-creating-equity-paradox", "who-glp1-conditional-endorsement-signals-system-readiness-gap", "who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap", "who-glp1-behavioral-supplement-low-certainty-evidence", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints"]
+---
+
+# WHO issued conditional (not strong) recommendation for GLP-1 obesity treatment with <10% projected global access by 2030 confirming structural barriers limit population-level impact of clinically proven interventions
+
+The WHO guideline represents a critical policy signal: despite moderate-certainty evidence of efficacy from trials of liraglutide, semaglutide, and tirzepatide, the organization issued a conditional rather than strong recommendation. The conditionality is explicitly attributed to non-clinical factors: 'high current costs,' 'inadequate health system readiness globally,' 'potential equity implications,' and 'variability in patient priorities and context-specific feasibility.' Most significantly, the WHO projects that 'fewer than 10% of people who could benefit' will have access to GLP-1 therapies by 2030, even under optimistic scenarios. This represents approximately 100 million people accessing treatment out of a global obesity burden exceeding 1 billion. The guideline explicitly warns that 'without deliberate policies, access could exacerbate existing health disparities' and calls the situation 'a profound equity dilemma.' The WHO's statement that 'medicines alone will not solve the problem' and that 'obesity is not only an individual concern but also a societal challenge that requires multisectoral action' directly validates the framework that structural and behavioral factors dominate population health outcomes even when pharmaceutical interventions are clinically effective. The 90% non-access projection is the inverse confirmation of the 10-20% medical care contribution to health outcomes.

inbox/archive/health/2025-12-01-who-glp1-obesity-guideline-conditional.md

@@ -7,9 +7,12 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: policy-document
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-26
 priority: high
 tags: [glp-1, WHO, obesity, global-health, equity, access, conditional-recommendation, health-system-preparedness]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content